Move optimally positions InSphero to build on its business development, scientific research, and operational teams
InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company will relocate its corporate headquarters and research and bioproduction laboratories to a larger facility in the Bio-Technopark Schlieren-Zürich life sciences building complex, positioned in the heart of the greater Zürich biotechnology hub. The new headquarters will almost double the company’s laboratory space and administrative office space, and optimally positions InSphero to expand as the company prepares for its next phase of growth as a biotechnology company that is transforming complex disease discovery, translational toxicology, and phenotypic preclinical modelling to advance human health.
“This move represents a significant milestone in InSphero’s history and marks the next step in our evolution as an innovative biotech that is redefining traditional drug discovery and safety testing paradigms for the pharmaceutical industry,” says InSphero CEO and co-founder Jan Lichtenberg, PhD. “Our new headquarters will provide an inspiring work environment for our employees, with state-of-the-art laboratories that will enable our scientists to optimize R&D workflows that incorporate our trailblazing technology and better support our growing roster of partnerships with researchers in pharma, biotech, and academia.”
InSphero has signed a long-term lease with Bio-Technopark Schlieren-Zürich, with an option to further expand within the next 3-5 years. The move, which will be completed on July 1, 2020, will not impact laboratory operations or customer service.